Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

Learn more about:
Related Clinical Trial
Induction of Cortical Plasticity S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Comparing Immobilisation Shells in Cranial Radiotherapy FBY PET/CT in Patients With Brain Tumors Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Prevalence of Post-craniotomy Headache in Siriraj Hospital Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma Wise Cortical Strip for Intraoperative Neurophysiological Monitoring Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) A Study of Cognitive Changes in Patients Receiving Brain Radiation

Brief Title

Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

Official Title

Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy

Brief Summary

      RATIONALE: Diagnostic procedures, such as magnetic resonance imaging, may help doctors
      predict a patient's response to treatment and help plan the best treatment. PURPOSE: This
      clinical trial is studying magnetic resonance imaging in response to radiation therapy in
      patients with high grade glioma.

Detailed Description

      Detailed DescriptionOBJECTIVES:

      I. To develop a multimodality statistical model to act as a surrogate marker scheme of early
      changes in high grade glioma patients undergoing radiation therapy, using conventional MRI,
      MR diffusion tensor imaging, perfusion, permeability, and spectroscopic imaging while
      incorporating the radiation dose calculations delivered locally and the results of a clinical
      questionnaire into the model.

      II. To assess treatment response to tumor and normal tissue changes. OUTLINE: Patients
      undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6, and then 4-6 weeks
      after completion of radiation therapy.

Study Type


Primary Outcome

Early brain tumor response

Secondary Outcome

 Early therapeutic-induced changes in normal surrounding brain


Brain Tumor


Magnetic Resonance Imaging

Study Arms / Comparison Groups

Description:  Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 2009

Completion Date

December 2012

Primary Completion Date

December 2012

Eligibility Criteria

        Inclusion Criteria:

          -  Patients being treated for diagnosed with high grade glioma (WHO grade III or IV) at
             the University of Pennsylvania Medical Center who will be undergoing radiation therapy
             to the brain

          -  Patient or legal representative able to provide written informed consent

          -  Adult males and nonpregnant females

        Exclusion Criteria:

          -  Vulnerable populations as specified (including pregnant patients, prisoners, patients
             with pacemakers or metallic implants)

          -  Patients with renal failure

          -  Patients with any condition considered a contraindication to MRI




18 Years - N/A

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

UPCC 12309

Responsible Party


Study Sponsor

Abramson Cancer Center of the University of Pennsylvania

Study Sponsor

, , 

Verification Date

December 2012